Can Fite Biopharma Ltd 's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Can Fite Biopharma Ltd 's ROA in the fourth quarter of 2025?
Can Fite Biopharma Ltd recorded a cumulative net loss of $-10 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -55.93%.

However, within the Healthcare sector 822 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4960.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	10.96 %	1.54 %	-14.49 %	4.32 %	3.97 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-10	-8	-8	-8	-8
Return On Assets (TTM)	-55.93 %	-47.77 %	-47.87 %	-46.94 %	-47.21 %
CANF's Total Ranking	# 4960	#	#	#	# 5138
Total Assets (TTM) in million	44	10	8	10	39
Seq. Total Assets Change	357.65 %	23.24 %	-18.86 %	-75.75 %	318.79 %
Seq. Net Income Change	-	-	-	-	-

CANF's 5 Years Annual ROA >> Back to CANF Management Effectiveness >> Compare CANF ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 381
Sector	# 823
Overall	# 4917

Return On Assets Statistics
High	Average	Low
-49.5 %	-100.81 %	-154.45 %
(Dec 31 2021)		(Dec 31 2019)

News about Can fite Biopharma Ltd Return on Assets ROA

Regulatory Advances and Financial Realities Can-Fite BioPharmas Journey with Namodenoson

In a significant advancement for pancreatic cancer treatment, Can-Fite BioPharma Ltd. has announced that its investigational oncology drug candidate, Namodenoson, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA). This designation is crucial for companies developing therapies for rare diseases, particularly in the context of aggressive malignancies like pancreatic cancer, which is notoriously difficult to treat and frequently associated with poor outcomes. The FDA s Orphan Drug Designation not only recognizes the unmet medical need in treating pancreatic cancer but also provides Can-Fite with several potential benefits, including market exclusivity for up to seven years post-approval. This exclusivity can be pivotal for a biopharmaceutical company looking to establish a foothold in a competitive market. Alongside this market advantage, the designation typically comes with regulatory incentives such as reduced fees and enhanced access to FDA s resources, which can facilitate more efficient clinical trial design and execution.Can-Fite s commitment to advancing Namodenoson aligns with its broader mission to develop proprietary small molecule drugs targeting oncological and inflammatory diseases. The development of Namodenoson, a compound that is thought to engage specific cellular pathways implicated in cancer, represents a potentially promising therapeutic avenue that could offer hope to patients suffering from one of the deadliest forms of cancer.

Can-Fite Biopharma From Loss to Opportunity with $325M Veterinary Licensing Agreement,

Can-Fite Biopharma: Turning a Loss into a $325 Million Opportunity with Veterinary Licensing AgreementIn the ever-evolving landscape of biotechnology, few stories emerge with the potential to reshape a company s fortunes like that of Can-Fite Biopharma Ltd. This Israeli biopharmaceutical company is poised for a significant turnaround after a notable partnership with Vetbiolix, which recently exercised its option to license Can-Fite s novel drug, Piclidenoson, for the treatment of osteoarthritis in dogs. With projected income estimates soaring up to $325 million over the next decade, the implications of this exciting development could signal a new chapter for Can-Fite.This agreement is anchored in the successful completion of clinical studies that validate the effectiveness of Piclidenoson in alleviating osteoarthritis symptoms in canines. As pet ownership and the demand for high-quality veterinary care continue to rise, Can-Fite may find itself at the forefront of a burgeoning market that values the health and well-being of beloved pets. This strategic partnership not only promises substantial financial returns but also positions Can-Fite as a pivotal player in the veterinary pharmaceutical space.

Financial Statements
Can Fite Biopharma Ltd 's Assets	$ 44 million	CANF's Balance sheet
Can Fite Biopharma Ltd 's Income	$ -10 million	Quarterly CANF's Income Statement
CANF's Income by Division		See CANF's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	14.14 %	1.07 %	-1.45 %	-24.74 %	6.55 %
Total Assets in million	44	38	38	38	51
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-10	-8	-8	-10	-10
Annual Return On Assets	-22.57 %	-20.66 %	-20.23 %	-26.56 %	-19.7 %

CANF's 5 Years Annual ROA >> Back to CANF Management Effectiveness >> Compare CANF ROA to its Competitors

More Return On Assets Ratios
CANF's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CANF's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CANF's Competitors
Subscribers only: Roa for Can Fite Biopharma Ltd 's Suppliers
Subscribers only: Return On Assets for CANF's Customers

You may also want to know
CANF's Roi	CANF's Inventory Turnover Ratio	CANF's Growth Rates	CANF's Dividend Comparisons
	CANF's Profitability Ratios	CANF's Asset Turnover Ratio	CANF's Dividend Growth
CANF's Roe	CANF's Valuation Ratios	CANF's Financial Strength Ratios	CANF's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.